We are live on ! Find out more
EMMA

Emmaus Life Sciences, Inc. Common Stock
EMMA

Delisted

EMMA was delisted on the 10th of September, 2019.

Back to rankings

9 hedge funds and large institutions have $79K invested in Emmaus Life Sciences, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more funds holding

Funds holding: 7 → 9 (+2)

11% more capital invested

Capital invested by funds: $71K → $79K (+$8K)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
9
Holders Change
+2
Holders Change %
+28.57%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Goldman Sachs
Goldman Sachs
New York
+$14.6K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$549
3
Bank of America
Bank of America
North Carolina
+$7

Top Sellers

1
UBS Group
UBS Group
Switzerland
-$2.82K
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
1
Cannell & Co
New York
$26K – – –
FFA
2
First Foundation Advisors
California
$21K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$16K +$549 +74 +4%
Goldman Sachs
4
Goldman Sachs
New York
$15K +$14.6K +1,969 New
UBS Group
5
UBS Group
Switzerland
$1K -$2.82K -380 -67%
Bank of America
6
Bank of America
North Carolina
– +$7 +1 New

EMMA Hedge Fund Activity: Q2 2019 in Review

9 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Emmaus Life Sciences, Inc. Common Stock (EMMA) for Q2 2019, worth a combined $79K — up 11% from $71K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new EMMA positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $14.6K. The largest seller was UBS Group, cutting an estimated $2.82K.

  • 9 institutional investors held Emmaus Life Sciences, Inc. Common Stock (EMMA) as of Q2 2019, up from 7 in Q1 2019.
  • Funds reported $79K of Emmaus Life Sciences, Inc. Common Stock stock for Q2 2019, up 11% quarter-over-quarter.
  • 2 funds opened new Emmaus Life Sciences, Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +2 holders.
  • The largest Emmaus Life Sciences, Inc. Common Stock buyer in Q2 2019 was Goldman Sachs, an estimated $14.6K added.
  • The largest Emmaus Life Sciences, Inc. Common Stock seller in Q2 2019 was UBS Group, an estimated $2.82K sold.

Based on aggregated 13F filings for Q2 2019.